Purified membrane fractions from mammary tumor cells elicit biological reactivity in in vitro cell-mediated immune reactions

Scot C. Buessow, Karen Caldwell, Mary A. Fletcher, Diana M Lopez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Lithium chloride (LiCl) aggregation followed by centrifugation through a sucrose step gradient was used to obtain purified plasma membranes from two sublines of mouse mammary adenocarcinoma. These two tumor lines were chemically induced by treatment of a hyperplastic nodule with 7,12-dimethylbenzanthracene (DMBA). One line, D1-DMBA-3, has been found to be immunogenic to the host of origin, while the other, D1-DMBA-2, does not elicit specific tumor immunity as previously tested in in vivo and in vitro immune reactions. The purified membrane fractions were assayed for protein, DNA and sialic acid content as well as enzymatic markers of membrane purity. When tested in blastogenesis and cytotoxicity reactions, membrane-containing fractions from the D1-DMBA-3 immunogenic tumor were found to be stimulatory to spleen cells of D1-DMBA-3 tumor bearers over a ten-fold protein concentration. Spleen cells from normal mice do not respond in these reactions to the various tumor fractions. No reactivity was observed when non-membrane-containing preparations were used as stimuli in the cell-mediated immune reactions. The specificity of these reactivities was further demonstrated by the lack of responses when fractions from the non-immunogenic D1-DMBA-2 tumor were tested in parallel in our in vitro assays. The data presented indicate that the procedure employed is useful for the isolation of membrane-associated, tumor-specific antigens which can be easily quantitated and still retain biological activity in in vitro tests of cell-mediated immunity.

Original languageEnglish
Pages (from-to)595-604
Number of pages10
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number6
DOIs
StatePublished - Jan 1 1982

Fingerprint

9,10-Dimethyl-1,2-benzanthracene
Breast Neoplasms
Membranes
Neoplasms
Spleen
Lithium Chloride
N-Acetylneuraminic Acid
Neoplasm Antigens
Lymphocyte Activation
Centrifugation
Cellular Immunity
Sucrose
In Vitro Techniques
Immunity
Proteins
Adenocarcinoma
Breast
Cell Membrane
DNA

ASJC Scopus subject areas

  • Oncology

Cite this

Purified membrane fractions from mammary tumor cells elicit biological reactivity in in vitro cell-mediated immune reactions. / Buessow, Scot C.; Caldwell, Karen; Fletcher, Mary A.; Lopez, Diana M.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 6, 01.01.1982, p. 595-604.

Research output: Contribution to journalArticle

@article{1d5c456698df4d67a21891139a2bb17c,
title = "Purified membrane fractions from mammary tumor cells elicit biological reactivity in in vitro cell-mediated immune reactions",
abstract = "Lithium chloride (LiCl) aggregation followed by centrifugation through a sucrose step gradient was used to obtain purified plasma membranes from two sublines of mouse mammary adenocarcinoma. These two tumor lines were chemically induced by treatment of a hyperplastic nodule with 7,12-dimethylbenzanthracene (DMBA). One line, D1-DMBA-3, has been found to be immunogenic to the host of origin, while the other, D1-DMBA-2, does not elicit specific tumor immunity as previously tested in in vivo and in vitro immune reactions. The purified membrane fractions were assayed for protein, DNA and sialic acid content as well as enzymatic markers of membrane purity. When tested in blastogenesis and cytotoxicity reactions, membrane-containing fractions from the D1-DMBA-3 immunogenic tumor were found to be stimulatory to spleen cells of D1-DMBA-3 tumor bearers over a ten-fold protein concentration. Spleen cells from normal mice do not respond in these reactions to the various tumor fractions. No reactivity was observed when non-membrane-containing preparations were used as stimuli in the cell-mediated immune reactions. The specificity of these reactivities was further demonstrated by the lack of responses when fractions from the non-immunogenic D1-DMBA-2 tumor were tested in parallel in our in vitro assays. The data presented indicate that the procedure employed is useful for the isolation of membrane-associated, tumor-specific antigens which can be easily quantitated and still retain biological activity in in vitro tests of cell-mediated immunity.",
author = "Buessow, {Scot C.} and Karen Caldwell and Fletcher, {Mary A.} and Lopez, {Diana M}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0277-5379(82)90230-9",
language = "English",
volume = "18",
pages = "595--604",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "6",

}

TY - JOUR

T1 - Purified membrane fractions from mammary tumor cells elicit biological reactivity in in vitro cell-mediated immune reactions

AU - Buessow, Scot C.

AU - Caldwell, Karen

AU - Fletcher, Mary A.

AU - Lopez, Diana M

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Lithium chloride (LiCl) aggregation followed by centrifugation through a sucrose step gradient was used to obtain purified plasma membranes from two sublines of mouse mammary adenocarcinoma. These two tumor lines were chemically induced by treatment of a hyperplastic nodule with 7,12-dimethylbenzanthracene (DMBA). One line, D1-DMBA-3, has been found to be immunogenic to the host of origin, while the other, D1-DMBA-2, does not elicit specific tumor immunity as previously tested in in vivo and in vitro immune reactions. The purified membrane fractions were assayed for protein, DNA and sialic acid content as well as enzymatic markers of membrane purity. When tested in blastogenesis and cytotoxicity reactions, membrane-containing fractions from the D1-DMBA-3 immunogenic tumor were found to be stimulatory to spleen cells of D1-DMBA-3 tumor bearers over a ten-fold protein concentration. Spleen cells from normal mice do not respond in these reactions to the various tumor fractions. No reactivity was observed when non-membrane-containing preparations were used as stimuli in the cell-mediated immune reactions. The specificity of these reactivities was further demonstrated by the lack of responses when fractions from the non-immunogenic D1-DMBA-2 tumor were tested in parallel in our in vitro assays. The data presented indicate that the procedure employed is useful for the isolation of membrane-associated, tumor-specific antigens which can be easily quantitated and still retain biological activity in in vitro tests of cell-mediated immunity.

AB - Lithium chloride (LiCl) aggregation followed by centrifugation through a sucrose step gradient was used to obtain purified plasma membranes from two sublines of mouse mammary adenocarcinoma. These two tumor lines were chemically induced by treatment of a hyperplastic nodule with 7,12-dimethylbenzanthracene (DMBA). One line, D1-DMBA-3, has been found to be immunogenic to the host of origin, while the other, D1-DMBA-2, does not elicit specific tumor immunity as previously tested in in vivo and in vitro immune reactions. The purified membrane fractions were assayed for protein, DNA and sialic acid content as well as enzymatic markers of membrane purity. When tested in blastogenesis and cytotoxicity reactions, membrane-containing fractions from the D1-DMBA-3 immunogenic tumor were found to be stimulatory to spleen cells of D1-DMBA-3 tumor bearers over a ten-fold protein concentration. Spleen cells from normal mice do not respond in these reactions to the various tumor fractions. No reactivity was observed when non-membrane-containing preparations were used as stimuli in the cell-mediated immune reactions. The specificity of these reactivities was further demonstrated by the lack of responses when fractions from the non-immunogenic D1-DMBA-2 tumor were tested in parallel in our in vitro assays. The data presented indicate that the procedure employed is useful for the isolation of membrane-associated, tumor-specific antigens which can be easily quantitated and still retain biological activity in in vitro tests of cell-mediated immunity.

UR - http://www.scopus.com/inward/record.url?scp=0019994702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019994702&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90230-9

DO - 10.1016/0277-5379(82)90230-9

M3 - Article

VL - 18

SP - 595

EP - 604

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 6

ER -